227 related articles for article (PubMed ID: 24071595)
1. Comparison of intravenous with oral busulfan in allogeneic hematopoietic stem cell transplantation with myeloablative conditioning regimens for pediatric acute leukemia.
Kato M; Takahashi Y; Tomizawa D; Okamoto Y; Inagaki J; Koh K; Ogawa A; Okada K; Cho Y; Takita J; Goto H; Sakamaki H; Yabe H; Kawa K; Suzuki R; Kudo K; Kato K
Biol Blood Marrow Transplant; 2013 Dec; 19(12):1690-4. PubMed ID: 24071595
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation.
Nagler A; Rocha V; Labopin M; Unal A; Ben Othman T; Campos A; Volin L; Poire X; Aljurf M; Masszi T; Socie G; Sengelov H; Michallet M; Passweg J; Veelken H; Yakoub-Agha I; Shimoni A; Mohty M
J Clin Oncol; 2013 Oct; 31(28):3549-56. PubMed ID: 23980086
[TBL] [Abstract][Full Text] [Related]
3. Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematopoietic stem cell transplantation.
Ansari M; Théoret Y; Rezgui MA; Peters C; Mezziani S; Desjean C; Vachon MF; Champagne MA; Duval M; Krajinovic M; Bittencourt H;
Ther Drug Monit; 2014 Feb; 36(1):93-9. PubMed ID: 24061446
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Outcomes for Pediatric Patients With Acute Myeloid Leukemia in Remission and Undergoing Allogeneic Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens Based on Either Intravenous Busulfan or Total Body Irradiation: A Report From the Japanese Society for Hematopoietic Cell Transplantation.
Ishida H; Kato M; Kudo K; Taga T; Tomizawa D; Miyamura T; Goto H; Inagaki J; Koh K; Terui K; Ogawa A; Kawano Y; Inoue M; Sawada A; Kato K; Atsuta Y; Yamashita T; Adachi S
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2141-2147. PubMed ID: 26271192
[TBL] [Abstract][Full Text] [Related]
5. [A comparison of toxicity and efficacy between busulfan plus fludarabine and busulfan plus cyclophosphamide for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia].
Liu H; Fan ZP; Jiang QL; Huang F; Zhou HS; Zhang X; Yu GP; Wu MQ; Sun J; Liu QF
Zhonghua Nei Ke Za Zhi; 2012 Nov; 51(11):880-4. PubMed ID: 23291027
[TBL] [Abstract][Full Text] [Related]
6. Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen.
Aggarwal C; Gupta S; Vaughan WP; Saylors GB; Salzman DE; Katz RO; Nance AG; Tilden AB; Carabasi MH
Biol Blood Marrow Transplant; 2006 Jul; 12(7):770-7. PubMed ID: 16785066
[TBL] [Abstract][Full Text] [Related]
7. Intravenous busulfan-cyclophosphamide as a preparative regimen before allogeneic hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia.
Tang W; Wang L; Zhao WL; Chen YB; Shen ZX; Hu J
Biol Blood Marrow Transplant; 2011 Oct; 17(10):1555-61. PubMed ID: 21549217
[TBL] [Abstract][Full Text] [Related]
8. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
[TBL] [Abstract][Full Text] [Related]
9. Superior survival after replacing oral with intravenous busulfan in autologous stem cell transplantation for non-Hodgkin lymphoma with busulfan, cyclophosphamide and etoposide.
Dean RM; Pohlman B; Sweetenham JW; Sobecks RM; Kalaycio ME; Smith SD; Copelan EA; Andresen S; Rybicki LA; Curtis J; Bolwell BJ
Br J Haematol; 2010 Jan; 148(2):226-34. PubMed ID: 19821828
[TBL] [Abstract][Full Text] [Related]
10. Busulfan pharmacokinetics do not predict relapse in acute myeloid leukemia.
Baker KS; Bostrom B; DeFor T; Ramsay NK; Woods WG; Blazar BR
Bone Marrow Transplant; 2000 Sep; 26(6):607-14. PubMed ID: 11041565
[TBL] [Abstract][Full Text] [Related]
11. Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation.
Bartelink IH; Bredius RG; Ververs TT; Raphael MF; van Kesteren C; Bierings M; Rademaker CM; den Hartigh J; Uiterwaal CS; Zwaveling J; Boelens JJ
Biol Blood Marrow Transplant; 2008 Jan; 14(1):88-98. PubMed ID: 18158965
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic transplantation with myeloablative FluBu4 conditioning improves survival compared to reduced intensity FluBu2 conditioning for acute myeloid leukemia in remission.
Magenau JM; Braun T; Reddy P; Parkin B; Pawarode A; Mineishi S; Choi S; Levine J; Li Y; Yanik G; Kitko C; Churay T; Frame D; Riwes MM; Harris A; Bixby D; Couriel DR; Goldstein SC
Ann Hematol; 2015 Jun; 94(6):1033-41. PubMed ID: 25784222
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Cyclophosphamide Combined with Total Body Irradiation, Oral Busulfan, or Intravenous Busulfan for Allogeneic Hematopoietic Cell Transplantation in Adults with Acute Lymphoblastic Leukemia.
Mitsuhashi K; Kako S; Shigematsu A; Atsuta Y; Doki N; Fukuda T; Kanamori H; Onizuka M; Takahashi S; Ozawa Y; Kurokawa M; Inoue Y; Nagamura-Inoue T; Morishima Y; Mizuta S; Tanaka J;
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2194-2200. PubMed ID: 27638362
[TBL] [Abstract][Full Text] [Related]
14. Impact of conditioning regimen in allogeneic hematopoetic stem cell transplantation for children with acute myelogenous leukemia beyond first complete remission: a pediatric blood and marrow transplant consortium (PBMTC) study.
Sisler IY; Koehler E; Koyama T; Domm JA; Ryan R; Levine JE; Pulsipher MA; Haut PR; Schultz KR; Taylor DS; Frangoul HA
Biol Blood Marrow Transplant; 2009 Dec; 15(12):1620-7. PubMed ID: 19896086
[TBL] [Abstract][Full Text] [Related]
15. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
[TBL] [Abstract][Full Text] [Related]
16. Once-daily intravenous busulfan for 47 pediatric patients undergoing autologous hematopoietic stem cell transplantation: a single center study.
González-Vicent M; Molina B; Pérez A; Díaz MA
J Pediatr Hematol Oncol; 2012 Apr; 34(3):180-3. PubMed ID: 22430583
[TBL] [Abstract][Full Text] [Related]
17. Comparison of outcomes of allogeneic transplantation for chronic myeloid leukemia with cyclophosphamide in combination with intravenous busulfan, oral busulfan, or total body irradiation.
Copelan EA; Avalos BR; Ahn KW; Zhu X; Gale RP; Grunwald MR; Hamadani M; Hamilton BK; Hale GA; Marks DI; Waller EK; Savani BN; Costa LJ; Ramanathan M; Cahn JY; Khoury HJ; Weisdorf DJ; Inamoto Y; Kamble RT; Schouten HC; Wirk B; Litzow MR; Aljurf MD; van Besien KW; Ustun C; Bolwell BJ; Bredeson CN; Fasan O; Ghosh N; Horowitz MM; Arora M; Szer J; Loren AW; Alyea EP; Cortes J; Maziarz RT; Kalaycio ME; Saber W
Biol Blood Marrow Transplant; 2015 Mar; 21(3):552-8. PubMed ID: 25528388
[TBL] [Abstract][Full Text] [Related]
18. Safe administration of oral BU twice daily during conditioning for stem cell transplantation in a paediatric population: a comparative study between the standard 4-dose and a 2-dose regimen.
Mellgren K; Nilsson C; Fasth A; Abrahamsson J; Winiarski J; Ringdén O; Hassan M
Bone Marrow Transplant; 2008 Apr; 41(7):621-5. PubMed ID: 18084338
[TBL] [Abstract][Full Text] [Related]
19. Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine/busulfan.
Shimoni A; Hardan I; Shem-Tov N; Rand A; Herscovici C; Yerushalmi R; Nagler A
Leukemia; 2007 Oct; 21(10):2109-16. PubMed ID: 17690701
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy and toxicity of intravenous busulfan-based conditioning before allogeneic peripheral blood stem cell transplantation for leukemia].
Tong XZ; Xu DR; Zou WY; Li J; Luo SK; Peng AH; Zhang GC; Zheng D
Ai Zheng; 2007 Aug; 26(8):914-8. PubMed ID: 17697559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
